Latest Safety News

Syntara Limited has reported positive final data from its Phase 2a trial of amsulostat in myelofibrosis, demonstrating significant symptom relief and spleen volume reduction with a favorable safety profile. These results pave the way for advancing clinical development and partnership discussions.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Newmont Corporation announces the retirement of CEO Tom Palmer at year-end 2025, with President and COO Natascha Viljoen stepping up as the first female CEO in the company’s century-long history.

Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.

Lindian Resources has adopted an owner-operator mining model at its Kangankunde Rare Earths Project, aiming to reduce mining costs by around 30% and accelerate production start to early 2026.

Aquirian Limited reports a 16.7% revenue increase alongside key operational advances at its Wubin facility and new leadership appointments, signaling strong momentum in mining services and technology.

WestStar Industrial’s subsidiary SIMPEC has landed a $115 million contract to expand residue filtration capacity at Alcoa’s Pinjarra Alumina Refinery, marking a key growth milestone.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

RocketDNA Ltd has landed a $450,000 contract with BHP Mitsubishi Alliance to operate three SurveyBot drone units over nine months, reinforcing its foothold in the mining sector.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.